Literature DB >> 1464487

Issues in the cross-national assessment of health technology.

M F Drummond1, B S Bloom, G Carrin, A L Hillman, H C Hutchings, R P Knill-Jones, G de Pouvourville, K Torfs.   

Abstract

With the growing international literature in economic evaluation and the rapid spread of new health technologies, there is a need to undertake, or at least interpret, economic evaluations on the international level. However, the ways in which cross-national differences affect the cost-effectiveness of health technologies or their evaluations have never been studied. This paper explores these issues by taking advantage of a unique situation in which the same economic evaluation of a new indication for a health technology was conducted simultaneously in four countries using an identical methodology. The study showed that if prior agreement on methods can be reached and local data applied, economic evaluations can be undertaken in a way that facilitates the extrapolation of results from country to country.

Mesh:

Substances:

Year:  1992        PMID: 1464487     DOI: 10.1017/s0266462300002361

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  31 in total

Review 1.  Design, analysis and presentation of multinational economic studies: the need for guidance.

Authors:  Francis Pang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  The pros and cons of a single 'Euro-price' for drugs.

Authors:  A Towse
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

3.  A decision chart for assessing and improving the transferability of economic evaluation results between countries.

Authors:  Robert Welte; Talitha Feenstra; Hans Jager; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 4.  Economic evaluation of pharmaceuticals: a European perspective.

Authors:  M Drummond; F Rutten; A Brenna; C G Pinto; B Horisberger; B Jönsson; C Le Pen; J Rovira; M G von der Schulenburg; H Sintonen
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

Review 5.  The generalisability of pharmacoeconomic studies.

Authors:  J Mason
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

Review 6.  Evaluating the impact of influenza vaccination. A North American perspective.

Authors:  D S Fedson
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 7.  Methodological issues in economic assessments of new therapies. The case of colony-stimulating factors.

Authors:  M Drummond; J Menzin; G Oster
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

8.  Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries.

Authors:  K Simpson; E J Hatziandreu; F Andersson; A Shakespeare; I Oleksy; A N Tosteson
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 9.  Current role of bone scan with phosphonates in the follow-up of breast cancer.

Authors:  Lorenzo Maffioli; Luigia Florimonte; Luca Pagani; Ivana Butti; Isabel Roca
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-16       Impact factor: 9.236

10.  Comparisons of hypertension-related costs from multinational clinical studies.

Authors:  C Daniel Mullins; Mirko Sikirica; Viran Seneviratne; Jeonghoon Ahn; Kasem S Akhras
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.